Spots Global Cancer Trial Database for MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
Official Title: A Phase I Dose Escalation Study of MK2461 in Patients With Advanced Cancer
Study ID: NCT00518739
Conditions
Interventions
Study Description
Brief Summary: This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Medical Monitor
Affiliation: Merck Sharp & Dohme LLC
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
